Small Molecule Drug Substance Outsourcing
Source: ISR Reports
In Q4 2020, ISR asked 123 outsourcers of small molecule API about the proportion of manufacturing allocated across three different approaches to outsourcing: tactical outsourcing, preferred providers, and strategic partnerships. The data show that the largest proportion of work is allocated tactically (38%), but that is expected to shift to preferred providers (41%) over the next three years as more outsourcers’ companies establish preferred relationships. To learn more, follow the link to the Small Molecule API CMO Quality Benchmarking report preview.
access the Infographic!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Subscribe to Pharmaceutical Online
X
Subscribe to Pharmaceutical Online
ISR Reports
This website uses cookies to ensure you get the best experience on our website. Learn more